Skip to content

Main menu

.

Network Chemotherapy Prescription Proformas/Protocols (NHS Staff use)

All patients should be tested for DPD deficiency before starting 5-fluorouracil (intravenous), capecitabine and tegafur. All relevant protocols will be updated with this requirement at their next review.

Full guidance below:

http://www.kmcc.nhs.uk/EasySiteWeb/GatewayLink.aspx?alId=467537

https://www.gov.uk/drug-safety-update/5-fluorouracil-intravenous-capecitabine-tegafur-dpd-testing-recommended-before-initiation-to-identify-patients-at-increased-risk-of-severe-and-fatal-toxicity

KMCC chemotherapy virology screening

Governance 

Access to Free of Charge Drugs Outside of Clinical Trials (via Access Schemes or Early Access to Medicine Schemes) v1

Overview 

Organisational Structure and Governance Processes for a Central Collaborative Team Supporting the Maintenance of Oncological Treatment Guidelines (treatment algorithms) and Systemic Anti-Cancer Therapy (SACT) Protocols in Oncology and Haematology across the Kent and Medway Cancer Collaborative v10


Guidance on capping of BSA for the purposes of calculating cytotoxic chemotherapy v1  


Policy for the Management of Algorithm deviations and the use of unfunded medicines which form part of treatment algorithms as defined in the Oncological Treatment Guidelines v6

SOPs 

SOP-001 Standard Operating Procedure for the Maintenance of the Kent and Medway Cancer Collaborative (KMCC) Regimens Spreadsheets for Oncology and Haematology v1


SOP-003 Standard Operating Procedure for the Development (or Update) and Approval of Kent & Medway Oncological Treatment Guidelines v2


SOP-004 Standard Operating Procedure for the Development (or Update) and Approval of Systemic Anticancer Therapy Protocols (SACT) v4


Protocols for Oral Anti-Cancer Treatments Dispensed in the Community

Imatinib for CML and Ph+ and ALL v2

UGI-015 Imatinib for Gastrointestinal Stromal Tumour (GIST) v4

UGI-056 Imatinib for ADJUVANT treatment of Gastrointestinal Stromal Tumour (GIST) v2


Supportive Care Guidelines & Supplementary Information Guidelines 

Cisplatin Hydration Guidelines v2 reviewed JULY 2020, no changes required and approved for use.

Guidelines for use of Rasburicase 

Guidelines for use of RASBURICASE v7

SOP for Carboplatin Desensitisation - Currently under review. For the latest protocol please refer to GYN-035 Carboplatin desensitisation found at:
http://www.kmcc.nhs.uk/medicines-and-prescribing-incorporating-sact-pathways/network-chemotherapy-prescription-proformas-protocols-nhs-staff-use/gynae-ovarian-and-uterine-sarcoma/

Information Sheets


 Procarbazine